Ibrutinib in Waldenström macroglobulinemia: latest evidence and clinical experience

Ther Adv Hematol. 2016 Aug;7(4):179-86. doi: 10.1177/2040620716654102. Epub 2016 Jun 13.


Ibrutinib is an oral Bruton's tyrosine kinase (BTK) inhibitor, which has recently gained approval by the United States (US) Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the treatment of patients with symptomatic Waldenström macroglobulinemia (WM). Herein, we review the role of BTK in the pathophysiology of WM, and present the results of the preclinical and clinical studies that led to the initial investigation and later approval of ibrutinib in WM. We also discuss aspects associated with ibrutinib therapy in WM patients, especially focusing on genomic profiling and the impact on response to ibrutinib, and the management of adverse events.

Keywords: Bruton’s tyrosine kinase; Waldenström macroglobulinemia; ibrutinib; lymphoplasmacytic lymphoma.

Publication types

  • Review